Calretinin is essential for mesothelioma cell growth/survival in vitro: A potential new target for malignant mesothelioma therapy?

International Journal of Cancer

Volumn 133, Issue 9, 2013, Pages 2077-2088

  Blum, Walter ^a   Schwaller, Beat ^a  

^a UNIVERSITY OF FRIBOURG   (Switzerland)

Author keywords

asbestos fibers; calretinin; cancer treatment; malignant mesothelioma; tumorigenesis

Indexed keywords

CALRETININ; CASPASE 9; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING;

ASBESTOS FIBERS; CALRETININ; CANCER TREATMENT; MALIGNANT MESOTHELIOMA; TUMORIGENESIS;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; EPITHELIUM; HUMANS; LENTIVIRUS; MESOTHELIOMA; MICE; PLEURAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SARCOMA;

EID: 84882640239     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28218     Document Type: Article

References (38)

1. Carbone M, Ly BH, Dodson RF, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 2011; 227: 44-58.
2. Belli C, Fennell D, Giovannini M, et al. Malignant pleural mesothelioma: current treatments and emerging drugs. Expert Opin Emerging Drugs 2009; 14: 423-37.
3. 12.1 subunit. J Biol Chem 2012; 287: 39766-75.
4. 2+ buffers. Cell Mol Life Sci 2008; 66: 275-300.
5. 2+ buffers. Cold Spring Harb Perspect Biol 2010; 2: a004051-1.
6. Billing-Marczak K, Kuznicki, J,. Calretinin-sensor or buffer-function still unclear. Pol J Pharmacol 1999; 51: 173-8.
7. 2+ buffers" parvalbumin, calbindin D-28k and calretinin in the brain. In:, Lajtha A, Banik N, eds. Handbook of neurochemistry and molecular neurobiology. Neural protein metabolism and function, Springer, New York, NY, vol. 7. 2007. 197-222.
8. Strauss KI, Isaacs KR, Ha QN, et al. Calretinin is expressed in the Leydig cells of rat testis. Biochim Biophys Acta 1994; 1219: 435-40.
9. Gotzos V, Vogt P, Celio MR,. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol Res Pract 1996; 192: 137-47.
10. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996; 20: 1037-46.
11. Husain AN, Colby TV, Ordõñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133: 1317-31.
12. Klebe S, Brownlee NA, Mahar A, et al. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol 2010; 23: 470-9.
13. Henzi T, Blum W-V, Pfefferli M, et al. SV40-induced expression of calretinin protects mesothelial cells from asbestos cytotoxicity and may be a key factor contributing to mesothelioma pathogenesis. Am J Pathol 2009; 174: 2324-36.
14. Yang H, Testa JR, Carbone M,. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol 2008; 9: 147-57.
15. Qi F, Carbone M, Yang H, et al. Simian virus 40 transformation, malignant mesothelioma and brain tumors. Expert Rev Respir Med 2011; 5: 683-97.
16. Jasani B, Gibbs A,. Mesothelioma not associated with asbestos exposure. Arch Pathol Lab Med 2012; 136: 262-7.
17. Gotzos V, Schwaller B, Gander JC, et al. Heterogeneity of expression of the calcium-binding protein calretinin in human colonic cancer cell lines. Anticancer Res 1996; 16: 3491-8.
18. Gander JC, Gotzos V, Fellay B, et al. Inhibition of the proliferative cycle and apoptotic events in WiDr cells after down-regulation of the calcium-binding protein calretinin using antisense oligodeoxynucleotides. Exp Cell Res 1996; 225: 399-410.
19. Marilley D,. Association between the calcium-binding protein calretinin and cytoskeletal components in the human colon adenocarcinoma cell line WiDr. Exp Cell Res 2000; 259: 12-22.
20. 2+-binding protein calretinin. Biochim Biophys Acta 2013; 1833:1680-91.
21. Antonov J, M.Sc., Redistribution of EGFP-calretinin fusion proteins in transfected CaCo-2 cells after butyrate treatment. University of Fribourg, Fribourg, Switzerland.
22. Kutner RH, Zhang X-Y, Reiser J,. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 2009; 4: 495-505.
23. Marilley D, Vonlanthen S, Gioria A, et al. Calretinin and calretinin-22k increase resistance toward sodium butyrate-induced differentiation in CaCo-2 colon adenocarcinoma cells. Exp Cell Res 2001; 268: 93-103.
24. Kitazume H, Kitamura K, Mukai K, et al. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining. Cancer 2000; 90: 55-60.
25. Sakaue-Sawano A, Kurokawa H, Morimura T, et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 2008; 132: 487-98.
26. Carbone M, Yang H,. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res 2012; 18: 598-604.
27. Izzi V, Masuelli L, Tresoldi I, et al. Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies. Cancer Lett 2012; 322: 18-34.
28. Shukla A, Barrett TF, MacPherson MB, et al. An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury. Am J Respir Cell Mol Biol 2011; 45: 906-14.
29. Casarsa C, Bassani N, Ambrogi F, et al. Epithelial-to-mesenchymal transition, cell polarity and stemness-associated features in malignant pleural mesothelioma. Cancer Lett 2011; 302: 136-43.
30. Schramm A, Opitz I, Thies S, et al. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. Eur J Cardiothorac Surg 2010; 37: 566-72.
31. Fassina A, Cappellesso R, Guzzardo V, et al. Epithelial-mesenchymal transition in malignant mesothelioma. Mod Pathol 2011; 25: 86-99.
32. Inase N, Miyake S, Yoshizawa Y,. Calretinin promoter for suicide gene expression in malignant mesothelioma. Anticancer Res 2001; 21: 1111-14.
33. Zhivotovsky B, Orrenius S,. Calcium and cell death mechanisms: a perspective from the cell death community. Cell Calcium 2011; 50: 211-21.
34. Cargnello R, Celio MR, Schwaller B, et al. Change of calretinin expression in the human colon adenocarcinoma cell line HT29 after differentiation. Biochim Biophys Acta 1996; 1313: 201-8.
35. Schwaller B, Herrmann B,. Regulated redistribution of calretinins in WiDr cells. Cell Death Differ 1997; 4: 325-33.
36. 2+-binding properties of human recombinant calretinin-22k and calretinin. J Biol Chem 1997; 272: 29663-71.
37. Sterman DH,. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005; 11: 7444-53.
38. Vachani A, Moon E, Albelda SM,. Gene therapy for mesothelioma. Curr Treat Options Oncol 2011; 12: 173-80.